(ALT) Altimmune - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 545m USD | Total Return: -49.7% in 12m
Avg Turnover: 10.2M
Warnings
Share dilution 64.7% YoY
Interest Coverage Ratio -34.6 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Confidence
Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical firm based in Gaithersburg, Maryland, specializing in treatments for liver disease and metabolic disorders. The company’s primary development focus is pemvidutide, a GLP-1/glucagon dual receptor agonist currently undergoing Phase 3 clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver conditions.
The biotechnology sector often requires significant capital expenditure and lengthy regulatory cycles, as clinical-stage companies typically lack commercial revenue until an FDA approval is secured. Altimmunes business model relies on intellectual property development and the successful navigation of multi-phase human trials to address high-unmet-need markets like obesity and liver fibrosis.
For a detailed breakdown of the companys valuation metrics and pipeline health, consider reviewing the latest data on ValueRay. Investors should monitor upcoming Phase 3 data readouts, as clinical trial results are the primary catalysts for stock volatility in the biotechnology industry.
- Pemvidutide Phase 3 clinical trial results drive long-term valuation prospects
- Strategic partnership or acquisition interest influences significant stock price volatility
- Competitive positioning against established GLP-1 therapies impacts market share projections
- Cash runway and future capital raises affect near-term shareholder dilution
- Regulatory approval milestones for MASH and obesity indications dictate commercial viability
| Net Income: -91.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA 25.38 > 1.0 |
| NWC/Revenue: 789k% < 20% (prev 727k%; Δ 61.3k% < -1%) |
| CFO/TA -0.21 > 3% & CFO -71.9m > Net Income -91.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 29.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (124.5m) vs 12m ago 64.75% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.02% > 50% (prev 0.01%; Δ 0.00% > 0%) |
| Interest Coverage Ratio: -34.61 > 6 (EBITDA TTM -93.5m / Interest Expense TTM 2.70m) |
| A: 0.96 (Total Current Assets 334.7m - Total Current Liabilities 11.3m) / Total Assets 335.6m |
| B: -2.00 (Retained Earnings -672.0m / Total Assets 335.6m) |
| C: -0.38 (EBIT TTM -93.6m / Avg Total Assets 246.4m) |
| D: -13.11 (Book Value of Equity -677.3m / Total Liabilities 51.6m) |
| Altman-Z'' = -16.53 = D |
| DSRI: 0.33 (Receivables 1.67m/2.46m, Revenue 41.0k/20.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.22 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 2.05 (Revenue 41.0k / 20.0k) |
| TATA: -0.06 (NI -91.1m - CFO -71.9m) / TA 335.6m) |
| Beneish M = -3.35 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 2.90 with a total of 1,988,383 shares traded.
Over the past week, the price has changed by +1.75%,
over one month by -16.43%,
over three months by -35.84% and
over the past year by -49.74%.
Altimmune has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy ALT.
- StrongBuy: 5
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.6 | 472.8% |
P/S = 15125.768
P/B = 1.9551
P/EG = 32.6168
Revenue TTM = 41.0k USD
EBIT TTM = -93.6m USD
EBITDA TTM = -93.5m USD
Long Term Debt = 34.3m USD (from longTermDebt, last fiscal year)
Short Term Debt = 265k USD (from shortTermDebt, last quarter)
Debt = 37.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.40m
Net Debt = -282.6m USD (calculated: Debt 37.2m - CCE 319.8m)
Enterprise Value = 261.9m USD (544.5m + Debt 37.2m - CCE 319.8m)
Interest Coverage Ratio = -34.61 (Ebit TTM -93.6m / Interest Expense TTM 2.70m)
EV/FCF = -3.47x (Enterprise Value 261.9m / FCF TTM -75.6m)
FCF Yield = -28.85% (FCF TTM -75.6m / Enterprise Value 261.9m)
FCF Margin = -184k% (FCF TTM -75.6m / Revenue TTM 41.0k)
Net Margin = -222k% (Net Income TTM -91.1m / Revenue TTM 41.0k)
Gross Margin = unknown ((Revenue TTM 41.0k - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = 0.78 (Enterprise Value 261.9m / Total Assets 335.6m)
Interest Expense / Debt = 7.26% (Interest Expense 2.70m / Debt 37.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -73.9m (EBIT -93.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 26.04 (Total Current Assets 334.7m / Total Current Liabilities 12.9m)
Debt / Equity = 0.13 (Debt 37.2m / totalStockholderEquity, last quarter 284.0m)
Debt / EBITDA = 3.02 (negative EBITDA) (Net Debt -282.6m / EBITDA -93.5m)
Debt / FCF = 3.74 (negative FCF - burning cash) (Net Debt -282.6m / FCF TTM -75.6m)
Total Stockholder Equity = 214.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.96% (Net Income -91.1m / Total Assets 335.6m)
RoE = -10.28% (Net Income TTM -91.1m / Total Stockholder Equity 886.0m)
RoCE = -10.17% (EBIT -93.6m / Capital Employed (Equity 886.0m + L.T.Debt 34.3m))
RoIC = -52.03% (negative operating profit) (NOPAT -73.9m / Invested Capital 142.1m)
WACC = 12.55% (E(544.5m)/V(581.8m) * Re(13.02%) + D(37.2m)/V(581.8m) * Rd(7.26%) * (1-Tc(0.21)))
Discount Rate = 13.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 39.93%
[DCF] Fair Price = unknown (Cash Flow -75.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.35 | # QB: 1
Revenue Correlation: -73.17 | Revenue CAGR: -68.98% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.16 | Chg30d=+36.58% | Revisions=+20% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.18 | Chg30d=+38.16% | Revisions=+20% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.76 | Chg30d=+34.87% | Revisions=+20% | GrowthEPS=+23.8% | GrowthRev=-88.9%
EPS next Year (2027-12-31): EPS=-0.97 | Chg30d=+29.03% | Revisions=+20% | GrowthEPS=-27.1% | GrowthRev=-100.0%
[Analyst] Revisions Ratio: +20%